

Manesh R Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3541258/publications.pdf>

Version: 2024-02-01

381
papers

43,750
citations

3159

92
h-index

2178

202
g-index

390
all docs

390
docs citations

390
times ranked

29231
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
2	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. <i>Journal of Vascular Surgery</i> , 2022, 75, 660-670.e3.	1.1	2
3	Trans-lesional fractional flow reserve gradient as derived from coronary CT improves patient management: ADVANCE registry. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 19-26.	1.3	20
4	Ambient temperature and infarct size, microvascular obstruction, left ventricular function and clinical outcomes after ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2022, 33, 81-90.	0.7	4
5	Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: a study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA). <i>British Journal of Sports Medicine</i> , 2022, 56, 913-918.	6.7	53
6	Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis. <i>Heart</i> , 2022, 108, 194-202.	2.9	45
7	Association between economic and arrhythmic burden of paroxysmal atrial fibrillation in patients with cardiac implanted electronic devices. <i>American Heart Journal</i> , 2022, 244, 116-124.	2.7	3
8	The prospective randomized trial of the optimal evaluation of cardiac symptoms and revascularization: Rationale and design of the PRECISE trial. <i>American Heart Journal</i> , 2022, 245, 136-148.	2.7	13
9	A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2022, 75, 1762-1775.	1.1	7
10	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
11	Patient-Reported Outcome Measures in Symptomatic, Non-“Limb-Threatening Peripheral Artery Disease: A State-of-the-Art Review. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011320.	3.9	5
12	1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 52-61.	2.9	35
13	Arrhythmic Burden and the Risk of Cardiovascular Outcomes in Patients With Paroxysmal Atrial Fibrillation and Cardiac Implanted Electronic Devices. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010304.	4.8	14
14	Coronary volume to left ventricular mass ratio in patients with diabetes mellitus. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 319-326.	1.3	3
15	Physician judgement in predicting obstructive coronary artery disease and adverse events in chest pain patients. <i>Heart</i> , 2022, , heartjnl-2021-320275.	2.9	3
16	Phenome-wide Association Study of Severe COVID-19 Genetic Risk Variants. <i>Journal of the American Heart Association</i> , 2022, 11, e024004.	3.7	10
17	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	3.8	3
18	Safety of the oral factor Xla inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. <i>Lancet, The</i> , 2022, 399, 1383-1390.	13.7	131

#	ARTICLE	IF	CITATIONS
19	Impact of risk factor control on peripheral artery disease outcomes and health disparities. <i>Vascular Medicine</i> , 2022, 27, 323-332.	1.5	2
20	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 793-794.	2.9	0
21	Electrocardiographic findings in young competitive athletes during acute SARS-CoV-2 infection. <i>Journal of Electrocardiology</i> , 2022, 72, 13-15.	0.9	4
22	Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. <i>Heart Rhythm</i> , 2022, 19, 1237-1244.	0.7	8
23	Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1469-1474.	1.7	4
24	Cardiovascular Outcomes in Collegiate Athletes After SARS-CoV-2 Infection: 1-Year Follow-Up From the Outcomes Registry for Cardiac Conditions in Athletes. <i>Circulation</i> , 2022, 145, 1690-1692.	1.6	17
25	Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 1863-1866.	27.0	1
26	One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 1011-1016.	3.9	6
27	Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE-HF trial cohort. <i>European Journal of Heart Failure</i> , 2022, 24, 1410-1414.	7.1	27
28	Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 825-836.	3.0	9
29	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
30	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
31	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. <i>JAMA Network Open</i> , 2022, 5, e2215580.	5.9	11
32	Clinical Outcomes in Patients With ST-Segment Elevation MI and No Standard Modifiable Cardiovascular Risk Factors. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1167-1175.	2.9	14
33	Temporal changes in FFRCT-Guided Management of Coronary Artery Disease – Lessons from the ADVANCE Registry. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 48-55.	1.3	5
34	Use of hospital resources in the care of patients with intermediate risk pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 273-278.	1.0	3
35	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.7	11
36	Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: An ACC PVI Registry Analysis. <i>American Heart Journal</i> , 2021, 233, 59-67.	2.7	4

#	ARTICLE	IF	CITATIONS
37	The clinical utility of FFRCT stratified by age. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 121-128.	1.3	6
38	Time Delay, Infarct Size, and Microvascular Obstruction After Primary Percutaneous Coronary Intervention for ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009879.	3.9	33
39	Response to: The paradox of implantable cardioverter-defibrillator: When guidelines play against care improvement. <i>American Heart Journal</i> , 2021, 233, 151-152.	2.7	0
40	Acute cardiovascular hospitalizations and illness severity before and during the <scp>COVID</scp>â€19 pandemic. <i>Clinical Cardiology</i> , 2021, 44, 656-664.	1.8	6
41	Successful Peripheral Vascular Intervention in Patients with High-risk Comorbidities or Lesion Characteristics. <i>Current Cardiology Reports</i> , 2021, 23, 32.	2.9	0
42	Renal Denervation for Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008301.	3.9	10
43	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	2.3	5
44	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. <i>International Journal of COPD</i> , 2021, Volume 16, 841-851.	2.3	6
45	Electronic Health Record Integration of Predictive Analytics to Select High-Risk Stable Patients With Nonâ€ST-Segmentâ€Elevation Myocardial Infarction for Intensive Care Unit Admission. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007602.	2.2	4
46	The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 796-802.	2.9	7
47	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heartâ€Failure. <i>JACC: Heart Failure</i> , 2021, 9, 293-300.	4.1	28
48	Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007232.	2.2	5
49	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	7.1	37
50	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4
51	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3016-3027.	2.8	23
52	National trends in repair for type B aortic dissection. <i>Clinical Cardiology</i> , 2021, 44, 1058-1068.	1.8	5
53	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021, 2, 215-222.	1.7	1
54	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PADâ€Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.	2.8	30

#	ARTICLE	IF	CITATIONS
55	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	5.9	5
56	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009871.	3.9	2
57	SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes. <i>Circulation</i> , 2021, 144, 256-266.	1.6	204
58	Lymphatic Dysregulation in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 66-76.	2.8	38
59	Utility of High-Sensitivity Troponin Among Stable Patients With Chest Pain Undergoing Stress Imaging (from PROMISE). <i>American Journal of Cardiology</i> , 2021, 158, 148-149.	1.6	1
60	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25
61	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021, 42, 4040-4048.	2.2	13
62	The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease. <i>American Heart Journal</i> , 2021, 239, 135-146.	2.7	12
63	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Anglo-iFR (ReVEAL iFR) study. <i>American Heart Journal</i> , 2021, 239, 19-26.	2.7	4
64	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	3.7	0
65	Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial. <i>American Heart Journal</i> , 2021, 242, 82-91.	2.7	0
66	Younger patients with chronic limb threatening ischemia face more frequent amputations. <i>American Heart Journal</i> , 2021, 242, 6-14.	2.7	3
67	The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target?. <i>Current Cardiology Reports</i> , 2021, 23, 13.	2.9	4
68	Crossing Peripheral Chronic Total Occlusions: More Tolls and More Questions. <i>Journal of the American Heart Association</i> , 2021, 10, e023423.	3.7	1
69	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.	1.6	19
70	Clinician specialty, access to care, and outcomes among patients with peripheral artery disease. <i>American Journal of Medicine</i> , 2021, , .	1.5	2
71	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.	2.8	19
72	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCel trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.8	6

#	ARTICLE	IF	CITATIONS
73	1-Year Impact on Medical Practice and Clinical Outcomes of FFRCT. JACC: Cardiovascular Imaging, 2020, 13, 97-105.	5.3	204
74	Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. American Heart Journal, 2020, 220, 51-58.	2.7	8
75	Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: A systematic review. American Heart Journal, 2020, 229, 52-60.	2.7	9
76	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009326.	3.9	7
77	Sex Differences in Coronary Computed Tomography Angiographyâ€œDerived Fractional Flow Reserve. JACC: Cardiovascular Imaging, 2020, 13, 2576-2587.	5.3	42
78	Cause of Death Among Patients With Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006550.	2.2	10
79	Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis, 2020, 315, 10-17.	0.8	17
80	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC: Cardiovascular Interventions, 2020, 13, 1617-1638.	2.9	60
81	Randomized Trials Versus Common Sense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	2.8	50
82	The impact of chronic kidney disease on outcomes following peripheral vascular intervention. Clinical Cardiology, 2020, 43, 1308-1316.	1.8	3
83	CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. American Heart Journal, 2020, 229, 118-120.	2.7	2
84	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006512.	2.2	16
85	Practice Pattern, Diagnostic Yield, and Long-Term Prognostic Impact of Coronary Computed Tomographic Angiography. Journal of the American Heart Association, 2020, 9, e016620.	3.7	4
86	Potential Association of the ISCHEMIA Trial With the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease. JAMA Internal Medicine, 2020, 180, 1540.	5.1	14
87	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq1 1 0.784314 rgBT ₇ /Overlo e016573.	3.7	7
88	SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention. Journal of Cardiovascular Pharmacology, 2020, 76, 189-196.	1.9	2
89	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	1.6	58
90	Non-hyperaemic coronary pressure measurements to guide coronary interventions. Nature Reviews Cardiology, 2020, 17, 629-640.	13.7	18

#	ARTICLE	IF	CITATIONS
91	Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 894-899.	2.4	62
92	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	4.1	44
93	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.	27.0	566
94	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 1444-1451.	13.7	351
95	Intensive Training and Real-Time Quality Control by a Physiology Core Laboratory. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009077.	3.9	2
96	Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006399.	2.2	23
97	Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 608-617.	2.8	30
98	Ischaemic stroke in heart failure: back to basics?. <i>Heart</i> , 2020, 106, 555-556.	2.9	1
99	Adherence to Guideline-Recommended Therapy Including Supervised Exercise Therapy Referral Across Peripheral Artery Disease Specialty Clinics: Insights From the International PORTRAIT Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e012541.	3.7	40
100	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	13.7	87
101	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	1.6	25
102	Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1743-1754.	2.8	41
103	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 20-29.	2.1	14
104	A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response. <i>American Heart Journal</i> , 2020, 225, 3-9.	2.7	12
105	Model-Based Algorithms for Detecting Peripheral Artery Disease Using Administrative Data From an Electronic Health Record Data System: Algorithm Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e18542.	2.6	10
106	Effect of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve on Physicians' Clinical Behavior: Differences Between Sites With and Without Appropriate Use Criteria as Designated by the Japanese Reimbursement System. <i>Circulation Reports</i> , 2020, 2, 364-371.	1.0	1
107	Abstract 17083: SARS-CoV-2 Dramatically Decreases Healthcare Access for Patients With Cardiovascular Disease. <i>Circulation</i> , 2020, 142, .	1.6	0
108	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2

#	ARTICLE	IF	CITATIONS
109	Identification, diagnosis, treatment, and in-hospital outcomes of acute pulmonary embolism: Results from a single integrated health system. <i>American Heart Journal</i> , 2019, 216, 136-142.	2.7	6
110	Determinants of Rejection Rate for Coronary CT Angiography Fractional Flow Reserve Analysis. <i>Radiology</i> , 2019, 292, 597-605.	7.3	37
111	Blinded Physiological Assessment of Residual Ischemia After Successful Angiographic Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1991-2001.	2.9	147
112	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1384-1392.	3.2	12
113	Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease. <i>American Heart Journal</i> , 2019, 217, 42-51.	2.7	16
114	Impact of Procedural Bleeding in Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008069.	3.9	6
115	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019, 218, 110-122.	2.7	7
116	Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain. <i>Journal of the American College of Cardiology</i> , 2019, 73, 251-260.	2.8	36
117	Impact of calcification on percutaneous coronary intervention: MACE Trial 1-year results. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 187-194.	1.7	36
118	Predictive Model for High-Risk Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e007940.	2.6	27
119	Global vascular guidelines on the management of chronic limb-threatening ischemia. <i>Journal of Vascular Surgery</i> , 2019, 69, 3S-125S.e40.	1.1	841
120	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80
121	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. <i>European Journal of Vascular and Endovascular Surgery</i> , 2019, 58, S1-S109.e33.	1.5	741
122	Sham trials: benefits and risks for cardiovascular research and patients. <i>Lancet, The</i> , 2019, 393, 2104-2106.	13.7	7
123	Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2251-2252.	2.8	0
124	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019, 50, 1356-1363.	2.0	33
125	Clinical Impact of Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve on Japanese Population in the ADVANCE Registry. <i>Circulation Journal</i> , 2019, 83, 1293-1301.	1.6	9
126	Identifying the Infarct-Related Artery in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007305.	3.9	32

#	ARTICLE	IF	CITATIONS
127	Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	10
128	Size of Anterior Wall Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention in United States Versus Europe/Australia Versus India (from the CRISP-AMI Randomized) Tj ETQq0 0 0 10 BT /Overlock 10 Tf	1.6	10
129	Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 2019, 40, 1568-1568.	2.2	3
130	PREPARED Study: A Study of Shared Decision-Making for Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005244.	2.2	29
131	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008018.	3.9	25
132	Polyvascular Disease. Circulation: Cardiovascular Interventions, 2019, 12, e007385.	3.9	51
133	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 145-152.	4.0	75
134	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal, 2019, 40, 1492-1500.	2.2	45
135	Percutaneous Support Devices for Percutaneous Coronary Intervention. Circulation, 2019, 139, 347-350.	1.6	4
136	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. European Heart Journal, 2019, 40, 743-751.	2.2	70
137	Ankle-brachial index in patients with intermittent claudication is a poor indicator of patient-centered and clinician-based evaluations of functional status. Journal of Vascular Surgery, 2019, 69, 906-912.	1.1	10
138	Endovascular treatment of femoro-popliteal lesions. Clinical Cardiology, 2019, 42, 175-183.	1.8	27
139	Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial. American Heart Journal, 2019, 208, 28-36.	2.7	20
140	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. JAMA Cardiology, 2019, 4, 7.	6.1	26
141	First-in-human experience with Aortix intraaortic pump. Catheterization and Cardiovascular Interventions, 2019, 93, 428-433.	1.7	29
142	High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD. JACC: Cardiovascular Imaging, 2019, 12, 1047-1055.	5.3	46
143	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83.	1.7	10
144	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. ASAIO Journal, 2018, 64, 218-224.	1.6	13

#	ARTICLE	IF	CITATIONS
145	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. American Heart Journal, 2018, 200, 102-109.	2.7	6
146	Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005628.	3.9	7
147	PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease:) Tj ETQq1 1 0,784314 rggBT /Ove	2.2	88
148	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clinical Cardiology, 2018, 41, 39-45.	1.8	11
149	Antithrombotic Therapy in Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 71, 352-362.	2.8	18
150	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). American Heart Journal, 2018, 199, 83-91.	2.7	104
151	Incidence and predictors of lesion-specific ischemia by FFRCT: Learnings from the international ADVANCE registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 95-100.	1.3	30
152	Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. Clinical Cardiology, 2018, 41, 137-143.	1.8	6
153	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. European Journal of Vascular and Endovascular Surgery, 2018, 55, 109-117.	1.5	28
154	Central Core Laboratory versus Site Interpretation of Coronary CT Angiography: Agreement and Association with Cardiovascular Events in the PROMISE Trial. Radiology, 2018, 287, 87-95.	7.3	49
155	Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain. JAMA Cardiology, 2018, 3, 144.	6.1	349
156	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. Progress in Cardiovascular Diseases, 2018, 60, 514-523.	3.1	11
157	The External Validity of Prediction Models for the Diagnosis of Obstructive Coronary Artery Disease in Patients With Stable Chest Pain. JACC: Cardiovascular Imaging, 2018, 11, 437-446.	5.3	44
158	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. Journal of the American College of Cardiology, 2018, 72, 3274-3284.	2.8	64
159	Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease. JAMA Network Open, 2018, 1, e185239.	5.9	68
160	Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization. Journal of the American College of Cardiology, 2018, 72, 1563-1572.	2.8	39
161	Twenty-Four Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. Circulation, 2018, 138, 1602-1604.	1.6	36
162	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. European Heart Journal, 2018, 39, 4255-4256.	2.2	54

#	ARTICLE	IF	CITATIONS
163	Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?. <i>Current Cardiology Reports</i> , 2018, 20, 105.	2.9	2
164	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008755.	3.7	21
165	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	13.7	597
166	Mature Technology for Mature Patients. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 889-891.	2.9	1
167	Splanchnic Nerve Block for Acute Heart Failure. <i>Circulation</i> , 2018, 138, 951-953.	1.6	62
168	Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. <i>Vascular Medicine</i> , 2018, 23, 523-530.	1.5	29
169	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018, 201, 25-32.	2.7	9
170	Should a Meta-Analysis Guide Our Practice?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 844-846.	2.9	2
171	Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry. <i>European Heart Journal</i> , 2018, 39, 3701-3711.	2.2	214
172	Effects of a 12-Week mHealth Program on Functional Capacity and Physical Activity in Patients With Peripheral Artery Disease. <i>American Journal of Cardiology</i> , 2018, 122, 879-884.	1.6	49
173	Odyssey of Patent Foramen Ovale: Closure in Cryptogenic Stroke: The Canary in the Coal Mine of Clinical Trials?. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	2
174	Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation. <i>Clinical and Experimental Emergency Medicine</i> , 2018, 5, 43-50.	1.6	1
175	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2212-2241.	2.8	513
176	Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. <i>American Heart Journal</i> , 2017, 188, 18-25.	2.7	17
177	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
178	Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing. <i>JAMA Cardiology</i> , 2017, 2, 400.	6.1	80
179	Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials. <i>European Heart Journal</i> , 2017, 38, 1656-1663.	2.2	56
180	Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	8

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.	1.7	11
182	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
183	Response by Jones et al to Letter Regarding Article, "Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease" <i>Circulation</i> , 2017, 135, e1109-e1110.	1.6	0
184	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	1.6	36
185	ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 1759-1792.	2.1	81
186	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 55</i>	1.6	74
187	Raising the pressure: Hemodynamic effects of splanchnic nerve stimulation. <i>Journal of Applied Physiology</i> , 2017, 123, 126-127.	2.5	30
188	National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension. <i>American Heart Journal</i> , 2017, 186, 29-39.	2.7	8
189	Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain. <i>Circulation</i> , 2017, 135, 2320-2332.	1.6	336
190	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. <i>New England Journal of Medicine</i> , 2017, 376, 1824-1834.	27.0	742
191	Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: Findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. <i>American Heart Journal</i> , 2017, 184, 1-9.	2.7	30
192	CHA 2 DS 2 -VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. <i>Annals of Emergency Medicine</i> , 2017, 69, 541-550.e1.	0.6	11
193	Rationale, design and goals of the HeartFlow assessing diagnostic value of non-invasive FFR CT in Coronary Care (ADVANCE) registry. <i>Journal of Cardiovascular Computed Tomography</i> , 2017, 11, 62-67.	1.3	45
194	Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2017, 119, 753-759.	1.6	15
195	Chronic Total Occlusion Trials. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2171-2173.	2.9	2
196	Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. <i>European Heart Journal</i> , 2017, 38, 3502-3510.	2.2	271
197	Morbidity and Mortality Conference for Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	13
198	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i> <i>Cardiology</i> , 2017, 120, 1837-1840.	2.6	10

#	ARTICLE	IF	CITATIONS
199	A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. <i>Current Medical Research and Opinion</i> , 2017, 33, 1717-1723.	1.9	4
200	The Effect of Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in Medicare Beneficiaries. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1161-1171.	2.9	26
201	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2017, 376, 32-40.	27.0	494
202	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
203	Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 105-120.	2.1	10
204	Patient-Reported Outcomes in Revascularization Decisions for Left-Main Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3123-3126.	2.8	0
205	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.7	597
206	The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 433-444.	2.6	4
207	Response by Fordyce et al to Letter Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF". <i>Circulation</i> , 2016, 134, e532-e533.	1.6	3
208	Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β : data from the Fabry Registry. <i>Journal of Medical Genetics</i> , 2016, 53, 495-502.	3.2	101
209	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , 2016, 134, e7-8.	1.6	1
210	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003070.	3.9	41
211	Relationship Between Infarct Size and Outcomes Following Primary PCI. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1674-1683.	2.8	444
212	Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization". <i>American Heart Journal</i> , 2016, 171, e7.	2.7	0
213	Practice Variation in Patients Eligible for Triple Therapy. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 44-46.	3.2	0
214	Peripheral Artery Disease Therapies May Perform Differently in Practice Than in Randomized Trials. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 725-727.	2.9	1
215	Quality-of-Life Outcomes With Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients With Suspected Coronary Artery Disease. <i>Circulation</i> , 2016, 133, 1995-2007.	1.6	35
216	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016, 18, 1135-1142.	1.7	31

#	ARTICLE	IF	CITATIONS
217	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
218	Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. <i>Molecular Genetics and Metabolism</i> , 2016, 119, 151-159.	1.1	35
219	Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). <i>American Journal of Medicine</i> , 2016, 129, 1307-1315.	1.5	5
220	Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. <i>American Heart Journal</i> , 2016, 179, 10-18.	2.7	14
221	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 435-445.	2.8	313
222	Location, Location, Location. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2400-2402.	2.9	1
223	A team-based approach to patients in cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 424-433.	1.7	67
224	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. <i>American Heart Journal</i> , 2016, 178, 74-84.	2.7	48
225	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2.	1.5	14
226	Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2888-2899.	2.8	171
227	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	2.7	51
228	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134
229	Clinical characteristics and outcomes after unplanned intraaortic balloon counterpulsation in the Counterpulsation to Reduce Infarct Size Pre-PCI Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2016, 174, 7-13.	2.7	3
230	Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. <i>Current Medical Research and Opinion</i> , 2016, 32, 1277-1279.	1.9	26
231	Point-of-Care Warfarin Monitoring in the ROCKET AF Trial. <i>New England Journal of Medicine</i> , 2016, 374, 785-788.	27.0	32
232	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	2.9	36
233	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. <i>American Heart Journal</i> , 2016, 175, 86-93.	2.7	41
234	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127

#	ARTICLE	IF	CITATIONS
235	Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes. American Heart Journal, 2016, 173, 57-66.	2.7	23
236	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133, 352-360.	1.6	141
237	Oral Anticoagulation in Patients with End Stage Renal Disease and Atrial Fibrillation. Circulation, 2016, 133, 242-244.	1.6	3
238	Usefulness of Intra-aortic Balloon Pump Counterpulsation. American Journal of Cardiology, 2016, 117, 469-476.	1.6	47
239	The Impact of Processes of Care on Myocardial Infarct Size in Patients With <scp>ST</scp>â€Segment Elevation Myocardial Infarction: Observations From the <scp>CRISPâ€AMI</scp> Trial. Clinical Cardiology, 2015, 38, 25-31.	1.8	2
240	Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban. Clinical Cardiology, 2015, 38, 63-68.	1.8	135
241	Comparative Effectiveness of Medical Therapy, Supervised Exercise, and Revascularization for Patients With Intermittent Claudication: A Network Metaâ€Analysis. Clinical Cardiology, 2015, 38, 378-386.	1.8	31
242	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	2.2	266
243	Limb Ischemia: Cardiovascular Diagnosis and Management from Head to Toe. Current Cardiology Reports, 2015, 17, 611.	2.9	19
244	Edoxaban and the need for outcomes-based NOAC dosing. Lancet, The, 2015, 385, 2232-2233.	18.7	5
245	Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. American Heart Journal, 2015, 169, 924-937.e3.	2.7	59
246	Use of Appropriate Use Criteria Is Increasing, but What Are Their Effects on Medical Care?. Circulation, 2015, 132, 4-6.	1.6	7
247	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2015, 4, e001349.	3.7	12
248	Letter response. American Heart Journal, 2015, 170, e5-e6.	2.7	4
249	Quality-of-Life and Economic Outcomes ofâ€Assessing Fractional Flow Reserve With Computed Tomography Angiography. Journal of the American College of Cardiology, 2015, 66, 2315-2323.	2.8	164
250	The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease. Circulation, 2015, 132, 1999-2011.	1.6	50
251	Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal of Medicine, 2015, 372, 1291-1300.	27.0	1,179
252	Evaluation and Treatment of Patients With Lower Extremity Peripheral Arteryâ€Disease. Journal of the American College of Cardiology, 2015, 65, 931-941.	2.8	269

#	ARTICLE	IF	CITATIONS
253	The Early Invasive Strategy in Acute Coronary Syndromes. Journal of the American College of Cardiology, 2015, 66, 521-523.	2.8	4
254	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 2015, 170, 675-682.e8.	2.7	128
255	Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis – Data from Life Line Screening®. Atherosclerosis, 2015, 241, 687-691.	0.8	45
256	Evaluation of Cardiac Magnetic Resonance as a Surrogate in ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2015, 115, 1607-1614.	1.6	4
257	Trends in Settings for Peripheral Vascular Intervention and the Effect of Changes in the Outpatient Prospective Payment System. Journal of the American College of Cardiology, 2015, 65, 920-927.	2.8	138
258	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet, The, 2015, 385, 2363-2370.	13.7	123
259	Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. European Journal of Preventive Cardiology, 2015, 22, 317-325.	1.8	94
260	Rationale and design of the Prospective Longitudinal Trial of FFRCT: Outcome and Resource Impacts study. American Heart Journal, 2015, 170, 438-446.e44.	2.7	15
261	Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. American Heart Journal, 2015, 170, 400-408.e1.	2.7	24
262	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR_{CT}: outcome and resource impacts study. European Heart Journal, 2015, 36, 3359-3367.	2.2	467
263	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. Journal of the American College of Cardiology, 2015, 66, 2271-2281.	2.8	159
264	Appropriate Use Criteria for Coronary Revascularization and Trends in Utilization, Patient Selection, and Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2015, 314, 2045.	7.4	212
265	Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial. European Heart Journal, 2015, 36, 219-227.	2.2	458
266	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. European Journal of Preventive Cardiology, 2015, 22, 734-742.	1.8	82
267	Intra-aortic balloon counterpulsation reduces mortality in large anterior myocardial infarction complicated by persistent ischaemia: a CRISP-AMI substudy. EuroIntervention, 2015, 11, 286-292.	3.2	30
268	Abstract 18053: Prognostic Value of Anatomic versus Functional Diagnostic Testing in Symptomatic Patients With Suspected CAD: The PROMISE Trial (PROspective Multicenter Imaging Study for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 13		
269	Abstract 17036: Uncontrolled Apparent Treatment Resistant Hypertension is Associated With Increased Hospitalization and Increased Total Hospital Reimbursements. Circulation, 2015, 132, .	1.6	0
270	Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial. Circulation, 2015, 132, .	1.6	0

#	ARTICLE	IF	CITATIONS
271	Abstract 16914: On-treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. <i>Circulation</i> , 2015, 132, .	1.6	0
272	Lower extremity amputation in peripheral artery disease: improving patient outcomes. <i>Vascular Health and Risk Management</i> , 2014, 10, 417.	2.3	59
273	Extent, Location, and Clinical Significance of Non-Infarct-Related Coronary Artery Disease Among Patients With ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2019.	7.4	263
274	Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?. <i>European Heart Journal</i> , 2014, 35, 1834-1835.	2.2	7
275	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	2.2	154
276	Clinical Trials in Peripheral Vascular Disease. <i>Circulation</i> , 2014, 130, 1812-1819.	1.6	40
277	Combined Use of Warfarin and Oral P2Y ₁₂ Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 152-159.	1.8	3
278	Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 142-150.	2.2	41
279	Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 1850-1859.	1.6	234
280	Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1754.	7.4	430
281	Patient Selection for Diagnostic Coronary Angiography and Hospital-Level Percutaneous Coronary Intervention Appropriateness. <i>JAMA Internal Medicine</i> , 2014, 174, 1630.	5.1	61
282	Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000521.	3.7	94
283	Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease. <i>Journal of the American Heart Association</i> , 2014, 3, e001330.	3.7	28
284	Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. <i>American Heart Journal</i> , 2014, 167, 846-852.e2.	2.7	218
285	PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. <i>American Heart Journal</i> , 2014, 167, 796-803.e1.	2.7	104
286	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
287	Analysis of Geographic Variations in the Diagnosis and Treatment of Patients With Aortic Stenosis in North Carolina. <i>American Journal of Cardiology</i> , 2014, 113, 1874-1878.	1.6	14
288	CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 143-156.	5.3	116

#	ARTICLE	IF	CITATIONS
289	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	2.2	145
290	ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 380-406.	2.8	580
291	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	2.0	187
292	Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. <i>European Heart Journal</i> , 2014, 35, 242-249.	2.2	82
293	Factors Associated With Major Bleeding Events. <i>Journal of the American College of Cardiology</i> , 2014, 63, 891-900.	2.8	212
294	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014, 168, 588-596.	2.7	44
295	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. <i>Lancet</i> , The, 2014, 384, 1187-1195.	13.7	123
296	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 233-241.	2.2	81
297	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	2.0	142
298	Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia. <i>American Heart Journal</i> , 2014, 167, 489-498.e7.	2.7	96
299	Association of the ankle-brachial index with history of myocardial infarction and stroke. <i>American Heart Journal</i> , 2014, 167, 499-505.	2.7	26
300	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Circulation</i> , 2014, 130, 138-146.	1.6	345
301	Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial. <i>Circulation</i> , 2014, 130, .	1.6	0
302	Appropriateness of Percutaneous Coronary Intervention: A Review. <i>Current Cardiology Reports</i> , 2013, 15, 379.	2.9	4
303	Aborted myocardial infarction after primary percutaneous coronary intervention: Magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. <i>American Heart Journal</i> , 2013, 165, 226-233.	2.7	7
304	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	2.8	181
305	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 224-232.	1.6	463
306	Intra-aortic Balloon Pump Trials. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 317-321.	3.9	22

#	ARTICLE	IF	CITATIONS
307	Appropriate Use of Cardiovascular Technology. Journal of the American College of Cardiology, 2013, 61, 1305-1317.	2.8	114
308	Reply. Journal of the American College of Cardiology, 2013, 61, 2025-2026.	2.8	0
309	High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. American Heart Journal, 2013, 165, 809-815.e1.	2.7	166
310	Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. Journal of the American College of Cardiology, 2013, 61, 1998-2006.	2.8	240
311	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 1268.	7.4	976
312	Importance of Total Ischemic Time and Preprocedural Infarct-Related Artery Blood Flow in Predicting Infarct Size in Patients With Anterior Wall Myocardial Infarction (from the CRISP-AMI Trial). American Journal of Cardiology, 2013, 112, 911-917.	1.6	12
313	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2013, 2, e000067.	3.7	179
314	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 740-747.	3.9	102
315	Ischemia-Driven Revascularization. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 250-252.	2.2	4
316	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 470-478.	2.2	39
317	Analysis of left ventricular mass in untreated men and in men treated with agalsidase- β : data from the Fabry Registry. Genetics in Medicine, 2013, 15, 958-965.	2.4	74
318	Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R ₂ CHADS ₂ Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition) Trial." JAMA, 2013, 309, 1268-1269.	1.6	5
319	2013, 128, e172-3. Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. Annals of Internal Medicine, 2013, 158, 861.	3.9	46
320	High Risk Percutaneous Coronary Intervention and Intra-Aortic Balloon Pumps. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 12-13.	2.2	0
321	Polyvascular Disease and Long-Term Cardiovascular Outcomes in Older Patients With Non-ST-Segment Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 541-549.	2.2	65
322	Hospital Percutaneous Coronary Intervention Appropriateness and In-Hospital Procedural Outcomes. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 290-297.	2.2	37
323	Obstructive Coronary Atherosclerosis and Ischemic Heart Disease: An Elusive Link!. Journal of the American College of Cardiology, 2012, 60, 951-956.	2.8	216
324	Appropriate Use Criteria to Reduce Underuse and Overuse. Journal of the American College of Cardiology, 2012, 60, 1885-1887.	2.8	18

#	ARTICLE	IF	CITATIONS
325	Temporal Trends and Geographic Variation of Lower-Extremity Amputation in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2230-2236.	2.8	158
326	Detecting Obstructive Coronary Disease With CT Angiography and Noninvasive Fractional Flow Reserve. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1269.	7.4	18
327	Downstream procedures and outcomes after stress testing for chest pain without known coronary artery disease in the United States. <i>American Heart Journal</i> , 2012, 163, 454-461.	2.7	33
328	Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. <i>American Heart Journal</i> , 2012, 163, 797-803.	2.7	6
329	The Study Of LoSmapiomod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. <i>American Heart Journal</i> , 2012, 164, 646-653.e3.	2.7	24
330	ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update. <i>Journal of the American College of Cardiology</i> , 2012, 59, 857-881.	2.8	447
331	ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1995-2027.	2.8	188
332	Comparative Effectiveness of Drug-Eluting Versus Bare-Metal Stents in Elderly Patients Undergoing Revascularization of Chronic Total Coronary Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1054-1061.	2.9	41
333	Missed Opportunities. <i>Circulation</i> , 2012, 126, 1345-1354.	1.6	147
334	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. <i>Lancet Neurology</i> , The, 2012, 11, 315-322.	10.2	310
335	Promise of Factor Xa Inhibition in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2012, 14, 70-78.	2.9	3
336	Cardiovascular Events in Patients With Fabry Disease. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1093-1099.	2.8	132
337	The Privilege of Self-Regulation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1557-1559.	2.8	15
338	Hospital Variability in the Rate of Finding Obstructive Coronary Artery Disease at Elective, Diagnostic Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2011, 58, 801-809.	2.8	88
339	2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. <i>Journal of the American College of Cardiology</i> , 2011, 58, e123-e210.	2.8	665
340	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 883-891.	27.0	8,006
341	A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: Rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial. <i>American Heart Journal</i> , 2011, 162, 47-55.e1.	2.7	18
342	Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. <i>European Heart Journal</i> , 2011, 32, 2387-2394.	2.2	536

#	ARTICLE	IF	CITATIONS
343	Appropriateness of Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2011, 306, 53-61.	7.4	314
344	Intra-aortic Balloon Counterpulsation and Infarct Size in Patients With Acute Anterior Myocardial Infarction Without Shock. JAMA - Journal of the American Medical Association, 2011, 306, 1329.	7.4	348
345	Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2011, 305, 1863.	7.4	203
346	Arteriotomy Closure Devices for Cardiovascular Procedures. Circulation, 2010, 122, 1882-1893.	1.6	136
347	ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2010, 55, 2614-2662.	2.8	559
348	Pexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2010, 3, 52-60.	5.3	37
349	Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal, 2010, 160, 272-278.	2.7	29
350	Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. American Heart Journal, 2010, 160, 795-803.e2.	2.7	23
351	Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine, 2010, 362, 886-895.	27.0	1,326
352	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Circulation, 2009, 119, 1330-1352.	1.6	271
353	Detection of Myocardial Damage in Patients With Sarcoidosis. Circulation, 2009, 120, 1969-1977.	1.6	610
354	Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genetics in Medicine, 2009, 11, 790-796.	2.4	252
355	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Catheterization and Cardiovascular Interventions, 2009, 73, E1-24.	1.7	41
356	ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization. Journal of the American College of Cardiology, 2009, 53, 530-553.	2.8	462
357	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	2.8	129
358	Detection of Left Ventricular Thrombus by Delayed-Enhancement Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2008, 52, 148-157.	2.8	271
359	ACCF/ASE/ACEP/AHA/ASNC/SCAI/SCCT/SCMR 2008 Appropriateness Criteria for Stress Echocardiography. Circulation, 2008, 117, 1478-1497.	1.6	112
360	Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers for Treating Essential Hypertension. Annals of Internal Medicine, 2008, 148, 16.	3.9	296

#	ARTICLE	IF	CITATIONS
361	Noninvasive imaging for coronary artery disease: A technology assessment for the Medicare Coverage Advisory Commission. American Heart Journal, 2007, 153, 161-174.	2.7	7
362	A Comparison of Acute Coronary Syndrome Care at Academic and Nonacademic Hospitals. American Journal of Medicine, 2007, 120, 40-46.	1.5	59
363	ACCF/AHA/ACEP/ASNC/SCAI/SCCT/SCMR 2007 Appropriateness Criteria for Transthoracic and Transesophageal Echocardiography—Developed in accordance with the principles and methodology outlined by ACCF: Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson E, Wolk MJ, Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005;46:1606-1613. Journal of the American College of Cardiology, 2006, 48, 1475-1497.	2.8	328
364	ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging—Developed in accordance with the principles and methodology outlined by ACCF: Patel MR, Spertus JA, Brindis RG, Hendel RC, Douglas PS, Peterson ED, Wolk MJ, Allen JM, Raskin IE. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005;46:1606-1613. Journal of the American College of Cardiology, 2006, 48, 1475-1497.	2.8	1,326
365	Clinical trial issues in weight-loss therapy. American Heart Journal, 2006, 151, 633-642.	2.7	18
366	Prevalence, predictors, and outcomes of patients with non-“ST-segment elevation myocardial infarction and insignificant coronary artery disease: Results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. American Heart Journal, 2006, 152, 641-647.	2.7	171
367	Acute Myocardial Infarction: Safety of Cardiac MR Imaging after Percutaneous Revascularization with Stents. Radiology, 2006, 240, 674-680.	7.3	37
368	Randomized trial for answers to clinical questions: evaluating a pre-appraised versus a MEDLINE search protocol. Journal of the Medical Library Association: JMLA, 2006, 94, 382-7.	1.7	8
369	Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). American Journal of Cardiology, 2005, 95, 614-618.	1.6	32
370	Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. American Journal of Cardiology, 2005, 95, 976-978.	1.6	85
371	Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. American Heart Journal, 2005, 149, 1043-1049.	2.7	256
372	ACCF/ASNC Appropriateness Criteria for Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI). Journal of the American College of Cardiology, 2005, 46, 1587-1605.	2.8	332
373	ACCF Proposed Method for Evaluating the Appropriateness of Cardiovascular Imaging. Journal of the American College of Cardiology, 2005, 46, 1606-1613.	2.8	300
374	Pexelizumab: A novel therapy for myocardial ischemia-reperfusion. Drugs of Today, 2005, 41, 165.	2.4	5
375	Access site for cardiac catheterization. American Heart Journal, 2004, 147, 1-2.	2.7	4
376	Which Î²-blocker for heart failure?. American Heart Journal, 2004, 147, 238.	2.7	0
377	To transfer or not to transfer: acute myocardial infarction reperfusion. American Heart Journal, 2004, 147, 573-574.	2.7	2
378	An Intracardiac Mass in a Young Man With Congenitally Acquired HIV. Cardiology in Review, 2004, 12, 126-130.	1.4	2

#	ARTICLE	IF	CITATIONS
379	Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation. <i>Drugs and Aging</i> , 2002, 19, 633-646.	2.7	11
380	The value of looking. Multiple myeloma discovered by an unusual finding in Gram-stained spinal fluid. <i>North Carolina Medical Journal</i> , 2002, 63, 129-30.	0.2	0
381	Stroke in Young Black Patients. <i>Stroke</i> , 1995, 26, 1995-1998.	2.0	102